新的心房指南:修改风险,控制节奏,防止进展
Laura A Campbell1, Jessica P Ammon2, Rachana Kombathula2
1Department of Medicine, Division of General Internal Medicine, University of Tennessee Health Science Center College of Medicine, Memphis, TN lcampb55@uthsc.edu.
Cleveland Clinic journal of medicine
|May 1, 2025
概括
2023年心房的指导方针更新了疾病分期和风险评估. 它优先考虑节律控制,并澄清导管切除标准,以改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 内部医学 内部医学
背景情况:
- 心房的管理指南随着新的证据和治疗选择而演变.
- 之前的指导方针提供了节奏和节律控制以及抗凝药的基本策略.
- 人们认识到需要更新的建议来解决当代治疗模式的需要.
研究的目的:
- 总结2023年美国心脏病学会/美国心脏协会/美国胸部医师学院/心律学会关于心房动的指南中的关键更新和建议.
- 突出疾病分期,风险分层和治疗策略的变化.
- 为临床医生提供当前基于证据的指导,用于管理心房动.
主要方法:
- 准则的制定涉及对现有文献和临床试验数据的全面审查.
- 专家的共识和系统审查为制定建议提供了信息.
- 该指南包含了关于抗凝血,节律控制和导管切除的新证据.
主要成果:
- 引入一种用于心房动的新型分期系统.
- 强调积极修改风险因素作为管理的基石.
- 在特定患者群体中,优先考虑节律控制策略而不是节律控制.
- 澄清了导管切除的适用情况.
- 针对抗凝固药治疗决策计算血栓形成风险的增强指南.
结论:
- 2023年指南代表了心房动管理的重大更新.
- 新方法强调基于风险分层和患者因素的个性化治疗.
- 该指南旨在通过更新的治疗策略和干预措施来优化患者的治疗结果.
相关概念视频
Disturbances in Heart Rhythm
737
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
737
Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
850
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
850
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
670
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
670
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K


